Synaptogenix (NASDAQ:SNPX) Shares Up 4.6% – What’s Next?

Synaptogenix, Inc. (NASDAQ:SNPX) shot up 4.6% on Wednesday . The stock traded as high as $4.29 and last traded at $4.10. 126,483 shares traded hands during trading, a decline of 44% from the average session volume of 225,669 shares. The stock had previously closed at $3.92.

Synaptogenix Stock Performance

The stock has a market capitalization of $5.70 million, a P/E ratio of -0.41 and a beta of 1.08. The firm has a fifty day moving average price of $2.62 and a two-hundred day moving average price of $2.84.

Synaptogenix (NASDAQ:SNPX) last posted its earnings results on Thursday, May 15th. The company reported $0.04 earnings per share for the quarter.

Hedge Funds Weigh In On Synaptogenix

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC purchased a new position in Synaptogenix, Inc. (NASDAQ:SNPX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.80% of Synaptogenix at the end of the most recent quarter. Institutional investors own 10.34% of the company’s stock.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.